Hananja

Emerging data presented by USL in San Diego Epilepsy and Neurology meetings 2012 & 2013

E-mail Print PDF

Upsher-Smith Laboratories released a press release on November 26th, 2012 on their committed to the development of new treatments for e.g. epilepsy. They are proud to sponsor emerging data on USL261, its novel formulation of intranasal midazolam, at the 66th Annual Meeting of the American Epilepsy Society (AES) in San Diego, CA, November 30 – December 4, 2012.

 

According to their press release: “USL261 (midazolam) is being developed for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters. This is a condition where few treatment options presently exist, particularly for the outpatient setting.” USL261 (midazolam) is a benzodiazepine in an investigational formulation that is delivered intranasally. It is intended to be administered by a caregiver in an outpatient setting for the rescue treatment of seizure clusters without active inhalation by the patient.

 

Upsher-Smith are sponsoring following presentations at the meeting (2012):

1. Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration, in Subjects with Epilepsy
2. Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam Optimized for Intranasal Administration, in Subjects with Epilepsy
3. Safety and Pharmacodynamics of USL261, a Novel Formulation of Intranasal Midazolam
4. Pharmacokinetics of USL261, A Novel Formulation of Intranasal Midazolam

 

Additional data are being presented at the 66th Annual Meeting of the American Academy of Neurology, March 16-23rd, San Diego, California

 

 
Þú ert hér: Home News Emerging data presented by USL in San Diego Epilepsy and Neurology meetings 2012 & 2013

Support center

Hananja plc

  • Address: Aflagrandi 7
  • City: 107 Reykjavík, Iceland
  • Tel: (+354) 898-0318
  • Email: sg@hananja.com